Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Bacterial Infections Suppress Immune Response in Neurodermatitis

By Drug Discovery Trends Editor | November 20, 2014

Skin of a patient with neurodermatitis (histological staining), which is covered with Staphylococcus aureus bacteria (dark dots on the surface and in the nick). (Credit: Y. Skabytska / Universität Tübingen)The skin condition neurodermatitis affects nearly one in four children and also occurs frequently in adults. Many patients also develop infections in the dry, open patches of skin, for example due to colonization by the pathogenic bacterium Staphylococcus aureus, which is particularly abundant on the skin of neurodermatitis patients. Scientists at Technische Universität München (TUM) and the University of Tübingen have now shown in an animal model that these infections can severely disrupt the immune system, thus aggravating the skin condition.
 
Because the skin and its function as a barrier are severely compromised in neurodermatitis patients, a large number of bacterial species are able to multiply – including the bacterium Staphylococcus aureus. Many patients have nearly 200-times as many S. aureus bacteria living on their skin as healthy individuals, resulting in frequent infections. Prof. Tilo Biedermann and his team at the Allergology and Dermatology Clinic of Klinikum rechts der Isar and the University of Tübingen have now shown in an animal model how these infections further aggravate the course of the disease.
 
Defense strategy against pathogens crippled
    
As a barrier against pathogenic microbes, the skin is equipped with a special alarm system – the toll-like receptors. These receptors recognize constituent substances of bacteria such as surface proteins and then activate the immune system. In their experiments, the scientists observed that cell wall proteins of S. aureus trigger the formation of a group of immune cells on the skin, known as myeloid-derived suppressor cells (MDSCs), via a new signal pathway. 
 
Under normal conditions, MDSCs regulate immune responses and inflammation by suppressing or stopping them at the right moment. In the experiment, however, the numerous bacterial proteins of S. aureus on the skin led to the excessive formation of MDSCs, resulting in the suppression of both harmful and beneficial immune responses in the skin. “That’s a very unfavorable development in the fight against the microbes. The MDSCs suppress protective defense strategies in the skin, thus exacerbating the consequences of the S. aureus infection,” explains Prof. Biedermann. 
 
More MDSCs in neurodermatitis patients
 
In addition to the animal model, the scientists also studied 33 patients with neurodermatitis and found that they have increased quantities of MDSCs in their blood and on their skin in comparison to healthy individuals. “This clinical observation confirms our findings. MDSCs appear to be particularly abundant in neurodermatitis patients, thus suppressing immune responses in the skin – with negative consequences for the course of the disease,” says Biedermann.
 
“Severely affected patients suffer considerably from chronic inflammation, itching and social stigmatization. Early, consistent treatment of patients that also targets the bacteria is very important,” he stresses. In the next step, he and his team aim to investigate how MDSCs normally terminate inflammation, and hope to use this knowledge to devise new therapeutic approaches against inflammatory skin diseases like neurodermatitis.
 
Source: Technische Universität München

Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE